Clinical trial shows synthetic cannabis reduces agitation in Alzheimer’s disease
Researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version of marijuana’s main ingredient, THC, reduces agitation in patients with Alzheimer’s by an average of 30%.
In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version …